Australia's Dimerix soars on commercialisation deal with Everest Medicines
16/06/2026 03:36
BUZZ-Australia's Dimerix soars on commercialisation deal with Everest Medicines ** Shares of Australia's Dimerix DXB.AX rise as much as 51.5% to A$0.250, their highest since April 30
** Clinical stage biopharmaceutical firm says it entered into an exclusive agreement with Everest Medicines 1952.HK
** Agreement to commercialise DMX-200 for the treatment of Focal
Segmental Glomerulosclerosis, a rare kidney disease, in Greater China, South Korea and Southeast Asia** Around 13.1 mln shares change hands, nearly 6.3x 30-day average
** DXB down 64.1% YTD
(Reporting by Keshav Singh Chundawat in Bengaluru)
Recent news on Dimerix
See all newsAustralia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions